Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carbamazepine effect on PF-07220060 pharmacokinetics in healthy adults
NCT06897683Phase 1Completed
- Sponsor
- Pfizer
- Start
- Mar 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of atirmociclib (2 arms), sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration at 120 hours and Area Under the Plasma Concentration Versus Time Curve at 120 hours. Started Mar 2025; status: completed.
02
Drugs
atirmociclib
Beyond the preview
Go deeper on NCT06897683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06897683.